Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Abstract

AA remains an orphan disease with limited systemic therapy options for patients who are not candidates for surgical resection. These data suggest activity from combined VEGF and PD-L1 inhibition that warrants further study.